0001209191-23-010972.txt : 20230217
0001209191-23-010972.hdr.sgml : 20230217
20230217213113
ACCESSION NUMBER: 0001209191-23-010972
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230215
FILED AS OF DATE: 20230217
DATE AS OF CHANGE: 20230217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McKenna Mark C.
CENTRAL INDEX KEY: 0001749623
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40187
FILM NUMBER: 23645032
MAIL ADDRESS:
STREET 1: 400 SOMERSET CORPORATE BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Prometheus Biosciences, Inc.
CENTRAL INDEX KEY: 0001718852
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 814282653
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3050 SCIENCE PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (858) 422-4300
MAIL ADDRESS:
STREET 1: 3050 SCIENCE PARK ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Precision IBD, Inc.
DATE OF NAME CHANGE: 20171004
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-15
0
0001718852
Prometheus Biosciences, Inc.
RXDX
0001749623
McKenna Mark C.
C/O PROMETHEUS BIOSCIENCES, INC.
3050 SCIENCE PARK ROAD
SAN DIEGO
CA
92121
1
1
0
0
Chairman, President & CEO
Common Stock
2023-02-15
4
M
0
25000
2.90
A
80144
D
Common Stock
2023-02-15
4
S
0
25000
119.42
D
55144
D
Common Stock
2023-02-16
4
M
0
25000
3.70
A
80144
D
Common Stock
2023-02-16
4
S
0
25000
119.87
D
55144
D
Common Stock
2023-02-17
4
M
0
13680
3.70
A
68824
D
Common Stock
2023-02-17
4
S
0
13680
125.10
D
55144
D
Stock Option (Right to Buy)
2.90
2023-02-15
4
M
0
25000
0.00
D
2029-11-06
Common Stock
25000
308633
D
Stock Option (Right to Buy)
3.70
2023-02-16
4
M
0
25000
0.00
D
2030-12-17
Common Stock
25000
506725
D
Stock Option (Right to Buy)
3.70
2023-02-17
4
M
0
13680
0.00
D
2030-12-17
Common Stock
13680
493045
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.
25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.
/s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna
2023-02-17